



(12) Translation of
European patent specification

(11) NO/EP 2512470 B1

NORWAY


(19) NO
(51) Int Cl.
A61K 31/426 (2006.01)
A61K 31/4436 (2006.01)
A61K 31/4439 (2006.01)
A61P 25/28 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.04.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.11.30
(86)	European Application Nr.	10798884.2
(86)	European Filing Date	2010.12.15
(87)	The European Application's Publication Date	2012.10.24
(30)	Priority	2009.12.15, US, 286713 P 2009.12.15, US, 286765 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Octeta Therapeutics, LLC, 161 East Michigan Avenue, 4th Floor, Kalamazoo MI 49007, US-USA
(72)	Inventor	COLCA, Gerard R., 125 South Kalamazoo Mall604, KalamazooMI 49007, US-USA KLETZIEN, Rolf F., 10264 W. Gull Lake Drive, RichlandMI 49083, US-USA TANIS, Steven P., 1750 Oriole Ct., CarlsbadCA 92011, US-USA LARSEN, Scott D., 13638 Cantaberry Ct., South LyonMI 48178, US-USA
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
(56)	References Cited:	WO-A1-2009/038681 WO-A1-2010/105048 WO-A2-2007/109024 GELDMACHER D S ET AL: "P1-397 Pioglitazone in Alzheimer's disease: rationale and clinical trial design", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 25, 1 July 2004 (2004-07-01), pages S211-S212, XP004625323, ISSN: 0197-4580, DOI: DOI:10.1016/S0197-4580(04)80709-7

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav**1.** Natriumsalt av forbindelsen X

Forbindelse X

5 for anvendelse i behandling av Parkinsons sykdom.